Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#152 of 388

Yasmeen Rahimi

Piper Sandler · Equity Research Analyst
ProvisionalRating since 2022No new ratings since Jun 2025

Analyst rating accuracy & track record

Yasmeen Rahimi is an equity research analyst at Piper Sandler. Quantellect has scored 23 of their stock calls across 16 companies. Their picks beat their sector 34% of the time over the next 12 months, and their price targets were reached 20% of the time within a year.

Win % vs sector
34%
PT Hit % (12mo)
20%
Avg sector-excess
−2.9%
Scored calls
23
Tickers
16
Tier
Provisional

Track record

Quantellect has scored 23 of Yasmeen Rahimi's stock calls across 16 companies, dating back to 2022. Their rated stocks beat their own sector 34% of the time over the next 12 months. On a typical call, a Rahimi pick returned −2.9% more than its sector over the following year.

Of the scored calls, 23 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
ALTAltimmune Inc
Buy$25.00Jun 2025−44.8%Miss
ALTAltimmune Inc
Buy$25.00Jun 2025−44.8%Miss
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$67.00Jun 2025−21.9%Miss
TVRDTvardi Therapeutics, Inc.
Buy$78.00Jun 2025−104.3%Miss
PRTAProthena Corporation plc
Buy$81.00May 2025+102.9%Miss
SLNOSoleno Therapeutics Inc
Buy$145.00Apr 2025−59.2%Miss
EWTXEdgewise Therapeutics Inc
Buy$51.00Apr 2025+141.0%Miss
LXRXLexicon Pharmaceuticals Inc
Buy$6.00Mar 2025+367.3%Miss
AVTXAvalo Therapeutics Inc
Buy$48.00Feb 2025+160.5%Miss
PRTAProthena Corporation plc
Buy$110.00Feb 2025−51.7%Miss
UPBUpstream Bio, Inc.
Buy$75.00Nov 2024−9.9%Miss
NKTRNektar Therapeutics
Buy$7.00Nov 2024+166.9%Miss
EWTXEdgewise Therapeutics Inc
Buy$51.00Oct 2024−47.1%Miss
ZURAZura Bio Limited Class A Ordinary Shares
Buy$26.00Sep 2024−45.1%Miss
ALTAltimmune Inc
Buy$25.00Jun 2024+6.5%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$30.00Jun 2024+130.6%Miss
ZURAZura Bio Limited Class A Ordinary Shares
Buy$26.00May 2024−68.6%Miss
UNCYUnicycive Therapeutics Inc
Buy$9.00Apr 2024−59.6%Miss
GOSSGossamer Bio Inc
Buy$15.00Mar 2024−1.4%Miss
ALGSAligos Therapeutics Inc
Buy$7.00Jan 2023−73.9%Miss
ALGSAligos Therapeutics Inc
Buy$3.00Jan 2023−50.0%Miss
PRAXPraxis Precision Medicines Inc
Buy$18.00Jun 2022−45.9%Miss
ALGSAligos Therapeutics Inc
Buy$15.00Mar 2022−44.9%Miss
Go to

Yasmeen Rahimi: analyst track record FAQ

Is Yasmeen Rahimi a good stock analyst?

Yes, by track record. Yasmeen Rahimi ranks number 152 of 388 of the analysts Quantellect scores, with a Q Score of 41 out of 100. Past results do not guarantee future ones.

What is Yasmeen Rahimi's win rate?

Yasmeen Rahimi's win rate is 34%. Across 23 scored calls, their rated stocks beat their sector 34% of the time over the next 12 months. On a typical call they returned −2.9% more than the sector.

What stocks and sectors does Yasmeen Rahimi cover?

Yasmeen Rahimi covers 16 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Yasmeen Rahimi's price targets accurate?

Yasmeen Rahimi's price targets are reached within 12 months 20% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Yasmeen Rahimi's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Yasmeen Rahimi rank among Wall Street analysts?

Yasmeen Rahimi ranks number 152 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.